Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miricorilant + olanzapine
- Development stage
- Phase 2
- Lead developer
- Corcept Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Miricorilant + olanzapine is a combination therapy consisting of miricorilant, a selective glucocorticoid receptor modulator, and olanzapine, an atypical antipsychotic. This combination is being investigated for its potential to mitigate the significant weight gain and metabolic disturbances commonly associated with olanzapine treatment. Clinical studies have shown that coadministration of miricorilant with olanzapine results in less weight gain and smaller increases in insulin, insulin resistance, triglycerides, and liver enzymes compared to olanzapine alone.
- Other names
- miricorilant + olanzapine
02
Targets
GR (Glucocorticoid receptor)MR (Mineralocorticoid receptor)
Beyond the preview
Go deeper on miricorilant + olanzapine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miricorilant + olanzapine.